Vonoprazan

Last updated

Vonoprazan
Vonoprazan structure.svg
Clinical data
Trade names Voquezna, others
AHFS/Drugs.com Voquezna
MedlinePlus a624006
License data
Routes of
administration 		By mouth
Drug class Potassium-competitive acid blocker
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability Unknown
Protein binding 80%
Metabolism Liver, by cytochrome P450 (3A4, 2B6, 2C19, 2D6)
Elimination half-life 7.7 h
Duration of action > 24 h
Excretion Kidney
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
Chemical and physical data
Formula C17H16FN3O2S
Molar mass 345.39 g·mol−1
3D model (JSmol)
  • Fc1ccccc1-c2cc(CNC)cn2S(=O)(=O)c3cccnc3
  • InChI=InChI=1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3
  • Key:BFDBKMOZYNOTPK-UHFFFAOYSA-N

Vonoprazan, sold under the brand name Voquezna among others, is a first-in-class potassium-competitive acid blocker medication. [2] [1] Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori . [2]

Contents

It was approved in Japan in February 2015, [3] [4] and in Russia in April 2021. [5] Vonoprazan was approved for medical use in the United States in November 2023. [1] [6] Co-packaged combinations of vonoprazan with amoxicillin and vonoprazan with amoxicillin and clarithromycin are available. [7] [8]

Medical uses

Vonoprazan is indicated for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults; to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults; in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection in adults; in combination with amoxicillin for the treatment of H. pylori infection in adults. [1] [7] [9]

In July 2024, the indication was expanded in the US to include non-erosive gastroesophageal reflux disease. [10]

Adverse effects

The most common side effects are constipation, diarrhea, enlarged feeling of abdomen, nausea, rash, and edema. [1] [11]

Long-term use may lead to vitamin B12 deficiency, hypomagnesemia, and fundic gland polyps. [11]

Society and culture

Names

Vonoprazan is the international nonproprietary name (INN). [12]

References

  1. 1 2 3 4 5 "Voquezna- vonoprazan fumarate tablet". DailyMed. 8 November 2023. Retrieved 20 November 2023.
  2. 1 2 Echizen H (April 2016). "The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations". Clinical Pharmacokinetics. 55 (4): 409–418. doi: 10.1007/s40262-015-0326-7 . PMID   26369775. S2CID   5984975.
  3. ↑ Garnock-Jones KP (2015). "Vonoprazan: first global approval". Drugs. 75 (4): 439–43. doi:10.1007/s40265-015-0368-z. PMID   25744862. S2CID   43293048.
  4. ↑ "Takecab Now Available for the Treatment of Acid-related Diseases in Japan". Takeda Pharmaceuticals (Press release). 26 February 2015. Archived from the original on 26 October 2023. Retrieved 20 November 2023.
  5. ↑ "Russian State Register of Medicines. Vocinti (vonoprazan) Film-Coated Tablets. Full Prescribing Information". grls.rosminzdrav.ru (in Russian). Takeda Pharmaceutical Company Limited. Archived from the original on 18 February 2023. Retrieved 18 February 2023.
  6. ↑ "Phathom Pharmaceuticals Announces Commercial Availability of Voquezna (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn". GlobeNewswire (Press release). Phathom Pharmaceuticals. 28 November 2023. Retrieved 26 January 2024.
  7. 1 2 "Voquezna Dual Pak- vonoprazan fumarate and amoxicillin kit; Voquezna Triple Pak- vonoprazan fumarate, amoxicillin and clarithromycin kit". DailyMed. 21 June 2022. Archived from the original on 3 July 2022. Retrieved 3 July 2022.
  8. ↑ "Phathom Pharmaceuticals Announces FDA Approval of Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults" (Press release). Phathom Pharmaceuticals. 3 May 2022. Archived from the original on 10 May 2022. Retrieved 9 May 2022– via GlobeNewswire.
  9. ↑ "Drug Approval Package: Voquezna". U.S. Food and Drug Administration (FDA). 8 June 2022. Archived from the original on 8 January 2023. Retrieved 3 February 2024.
  10. ↑ "Phathom Pharmaceuticals Announces FDA Approval of Voquezna (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults" (Press release). Phathom Pharmaceuticals. 18 July 2024. Retrieved 19 July 2024– via GlobeNewswire.
  11. 1 2 FDA Professional Drug Information
  12. ↑ World Health Organization (2012). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 68". WHO Drug Information. 26 (3). hdl: 10665/109813 .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.